Unlock future therapies with us
Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and most successful brands: creating, making, and selling speciality chemicals that are relied on by industries and consumers everywhere. We have a network of over 4,500 passionate and committed employees, working together as one global team across manufacturing sites and offices in 38 countries.
As Croda Pharma, we are committed to empowering biologics delivery. We offer high purity pharmaceutical excipients, world leading vaccine adjuvants, innovative lipids and in-house formulation expertise, making us the ideal partner to navigate drug and vaccine formulation challenges.
Tailored excipient solutions
Create tailored excipient solutions directly in partnership with our scientists.
We work with you to unlock future therapies through developing the next generation of excipients.
Formulate and troubleshoot faster
Tackle your stability challenges with unparalleled purity excipients across all administration routes.
Formulate and troubleshoot faster by working with our scientific experts during your development.
Sustainability
Prioritise sustainability and integrity by choosing Croda Pharma for your developments.
Your pharma solutions partner
Our technology platforms
We’re committed to investing in the next generation of excipients you need. Our teams work with you to troubleshoot formulations and develop research grade and GMP excipient solutions. Purity is our forte across our multi-compendial, GMP grade materials.
Small Molecule Delivery
Our portfolio of high purity excipient products and speciality chemistries solve formulation challenges and enhance drug delivery across a variety of administration routes and dosage forms.
Our portfolio of high purity excipient products and speciality chemistries solve formulation challenges and enhance drug delivery across a variety of administration routes and dosage forms.
Protein Delivery
Addressing the toughest challenges associated with protein-based therapies, our Super Refined™ range of high purity excipients ensures optimal protein stabilisation for enhanced biologic drug delivery.
Addressing the toughest challenges associated with protein-based therapies, our Super Refined™ range of high purity excipients ensures optimal protein stabilisation for enhanced biologic drug delivery.
Nucleic Acid Delivery
Our Avanti lipids range offers innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.
Our Avanti lipids range offers innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.
Adjuvant Systems
We enable next-generation vaccine development through a diverse portfolio of world-leading vaccine adjuvants, immunomodulators and adjuvant formulations.
We enable next-generation vaccine development through a diverse portfolio of world-leading vaccine adjuvants, immunomodulators and adjuvant formulations.
Find out more information on our markets:
Human Pharmaceuticals
We are transforming our business to meet the needs of the pharma industry, committing to product quality, regulatory excellence, and supply chain security.
Consumer Health
Our main goal in Consumer Health is to help our customers market consumer relevant label claims that grow their product and brand authority. We combine our technical expertise with regulatory knowledge to help our customers market innovative products.
Veterinary health
We create, make, and commercialise a wide range of specialty excipients which are used to enhance the delivery, efficacy, and stability of actives in many types of livestock and companion animal health products.
How we empower biologics delivery
Explore recent blogs:
Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4F9521E2A9CDAB872D1AA12B9BA9F4EB)
From Lab to Patient: Optimising Oncology Formulations with Purified Excipients
In 2024, we hosted a live webinar exploring the impact of our Super RefinedTM excipients on various chemotherapeutic formulations. This blog will explore some of the key learnings from the webinar.
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F330DFD631D5F6E81578038D37E005ED){kind=logo}
Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to...